Generation Bio Co (GBIO NASDAQ) stock market data APIs
$5.6942
-0.05(-0.9%)
as of February 3, 2026
Try our APIs with
free plan!
Generation Bio Co Financial Data Overview
Price chart is built with
Anychart
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Prev. Close
5.6942
Open
5.6458
High
5.757
Low
5.5114
52 wk Range
3-8.4
Market Cap
38 410 K
Shares Outstanding
6 739 K
Revenue
15 270 K
EPS
-0.82
Beta
2.006
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Generation Bio Co (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Generation Bio Co data using free add-ons & libraries
Get Generation Bio Co Fundamental Data
Generation Bio Co Fundamental data includes:
- Net Revenue: 15 270 K
- EBITDA: -76 380 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.28
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Generation Bio Co News
New
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval TORONTO, January 29, 2026--(BUSINESS WIRE)--Satellos Biosci...
Weekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances
(RTTNews) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis. - ScinoP...
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were a...
XOMA Strikes Deal To Acquire Generation Bio, Expanding Royalty Portfolio
(RTTNews) - XOMA Royalty Corporation (XOMA), a biotechnology royalty aggregator, has agreed to acquire Generation Bio Co. (GBIO), a clinical-stage company historically focused on T cell-driven autoimm...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
